Actively Recruiting
Precision Cancer Therapy in Rare Cancers
Led by Oslo University Hospital · Updated on 2025-03-26
96
Participants Needed
1
Research Sites
593 weeks
Total Duration
On this page
Sponsors
O
Oslo University Hospital
Lead Sponsor
H
Helse Stavanger HF
Collaborating Sponsor
AI-Summary
What this Trial Is About
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
CONDITIONS
Official Title
Precision Cancer Therapy in Rare Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 16 and 99 years
- Performance status (ECOG) of 0 to 2
- Presence of an identified biomarker
- Reasonable biochemistry results
You will not qualify if you...
- Performance status (ECOG) of 3 to 5
- Presence of serious other diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oslo University Hospital
Oslo, Norway, 0310
Actively Recruiting
Research Team
Å
Åslaug Helland, MD PhD
CONTACT
K
Kathinka Slørdahl, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here